Xing T. Zeng

No. 1095 Jiefang Ave
Wuhan, 430030, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 49 publications

Efficacy and Safety of Disitamab Vedotin Combined with Gemcitabine as Neoadjuvant Therapy in Muscle-invasive Bladder Cancer: An Open-label, Multicenter, Single-arm, Phase 2 Trial.

Efficacy and Safety of Disitamab Vedotin Combined with Gemcitabine as Neoadjuvant Therapy in Muscle-invasive Bladder Cancer: An Open-label, Multicenter, Single-arm, Phase 2 Trial.

Journal: European urology
Published: May 04, 2025

Tumor ABCC4-mediated release of PGE2 induces CD8+ T cell dysfunction and impairs PD-1 blockade in prostate cancer.

Tumor ABCC4-mediated release of PGE2 induces CD8+ T cell dysfunction and impairs PD-1 blockade in prostate cancer.

Journal: International journal of biological sciences
Published: June 17, 2024

68Ga-PSMA PET/CT and 18F-FDG PET/CT in the diagnosis of prostatic ductal cancer.

68Ga-PSMA PET/CT and 18F-FDG PET/CT in the diagnosis of prostatic ductal cancer.

Journal: Urologic oncology
Published: March 14, 2024

Targeting oxidative phosphorylation to increase the efficacy of immune-combination therapy in renal cell carcinoma.

Targeting oxidative phosphorylation to increase the efficacy of immune-combination therapy in renal cell carcinoma.

Journal: Journal for immunotherapy of cancer
Published: January 22, 2024

Comparing the diagnostic value of 68Ga-prostate-specific membrane antigen PET/CT and multiparametric MRI in pelvic lymph node metastasis of locally advanced prostate cancer.

Comparing the diagnostic value of 68Ga-prostate-specific membrane antigen PET/CT and multiparametric MRI in pelvic lymph node metastasis of locally advanced prostate cancer.

Journal: Translational andrology and urology
Published: January 15, 2024

Targeting Alpha-Ketoglutarate Disruption Overcomes Immunoevasion and Improves PD-1 Blockade Immunotherapy in Renal Cell Carcinoma.

Targeting Alpha-Ketoglutarate Disruption Overcomes Immunoevasion and Improves PD-1 Blockade Immunotherapy in Renal Cell Carcinoma.

Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)
Published: March 27, 2023

Development and validation of a prognostic model incorporating tumor thrombus grading for nonmetastatic clear cell renal cell carcinoma with tumor thrombus: A multicohort study.

Development and validation of a prognostic model incorporating tumor thrombus grading for nonmetastatic clear cell renal cell carcinoma with tumor thrombus: A multicohort study.

Journal: MedComm
Published: March 09, 2023

Prognostic Significance of Grade Discrepancy Between Primary Tumor and Venous Thrombus in Nonmetastatic Clear-cell Renal Cell Carcinoma: Analysis of the REMEMBER Registry and Implications for Adjuvant Therapy.

Prognostic Significance of Grade Discrepancy Between Primary Tumor and Venous Thrombus in Nonmetastatic Clear-cell Renal Cell Carcinoma: Analysis of the REMEMBER Registry and Implications for Adjuvant Therapy.

Journal: European urology oncology
Published: February 17, 2023

The diagnostic value of fluorescence in situ hybridization in secondary electroresection of bladder cancer.

The diagnostic value of fluorescence in situ hybridization in secondary electroresection of bladder cancer.

Journal: Bladder (San Francisco, Calif.)
Published: January 19, 2023

Metabolic classifications of renal cell carcinoma reveal intrinsic connections with clinical and immune characteristics.

Metabolic classifications of renal cell carcinoma reveal intrinsic connections with clinical and immune characteristics.

Journal: Journal of translational medicine
Published: January 08, 2023

Neoadjuvant therapy with Disitamab vedotin in treating muscle-invasive bladder cancer: A case report.

Neoadjuvant therapy with Disitamab vedotin in treating muscle-invasive bladder cancer: A case report.

Journal: Heliyon
Published: November 12, 2022

Non-SMC condensin I complex subunit H participates in anti-programmed cell death-1 resistance of clear cell renal cell carcinomas.

Non-SMC condensin I complex subunit H participates in anti-programmed cell death-1 resistance of clear cell renal cell carcinomas.

Journal: Cell proliferation
Published: September 18, 2022
Showing 1-12 of 49

Last Updated: 09/26/2026